Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy

Tumori. 1991 Dec 31;77(6):506-10.

Abstract

CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvages chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Small Cell / drug therapy*
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Drug Resistance
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Lomustine / administration & dosage
  • Lung Neoplasms / drug therapy*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Remission Induction
  • Salvage Therapy*
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Etoposide
  • Lomustine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Methotrexate

Supplementary concepts

  • CAV protocol